Depomed (DEPO) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Depomed Reports Second Quarter 2016 Financial Results
August 3, 2016 4:01 PM EDT- Second Quarter Revenues of $117 million, 23% over 2Q 2015 -- NUCYNTA® Franchise Second Quarter 2016 Record Net Sales of $72 million, 27% over 2Q 2015 -- Conference Call Scheduled for Today at 4:30 PM EDT; Dial In Information Below -
NEWARK, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended June 30, 2016.
"The second quarter marked the 1-year anniversary of the mid-June relaunch of our flagship NUCYNTA franchise, said Jim Schoeneck, President and CEO of Depomed. During the first full year after our relaunch, we delivered... More
